Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Translational Neuroscience

Editor-in-Chief: David, Olivier

1 Issue per year

IMPACT FACTOR 2017: 0.833
5-year IMPACT FACTOR: 1.247

CiteScore 2017: 1.00

SCImago Journal Rank (SJR) 2017: 0.428
Source Normalized Impact per Paper (SNIP) 2017: 0.244

Open Access
See all formats and pricing
More options …

CSF tau proteins in differential diagnosis of dementia

Marina Boban
  • School of Medicine, University of Zagreb, Zagreb, Croatia
  • Department of Neurology, University Hospital Centre Zagreb, Zagreb, Croatia
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Helena Šarac / Ninoslav Mimica / Mihovil Mladinov / Christine Süßmair / Nibal Ackl / Benedikt Bader / Miljenko Huzak / Adrian Danek / Patrick Hof / Goran Šimić
Published Online: 2010-10-12 | DOI: https://doi.org/10.2478/v10134-010-0013-z


Alzheimer’s disease (AD) and frontotemporal lobar degeneration (FTLD) represent an important differential diagnostic problem in clinical practice. The identification for new biomarkers that would help establishing the diagnosis and primary cause of the dementia is therefore highly relevant. The aim of this study was to investigate the diagnostic accuracy of three potential CSF biomarkers, total tau protein (t-tau), tau protein phosphorylated at threonine 181 (p-tau181), and tau protein phosphorylated at serine 199 (p-tau199) in the differential diagnosis of AD and FTLD patients in relatively young age groups. The concentrations of the three CSF biomarkers were measured in 25 FTLD patients, 27 AD patients, and 25 non-demented (ND) subjects. The CSF concentrations of all three markers were significantly higher in AD than in FTLD cases (p < 0.001) or ND controls (p < 0.001). No difference was observed in FTLD compared to the ND group, except for p-tau181 (p = 0.028). When sensitivity was set at 85% or higher, specificity in differentiation between FTLD and AD patients reached 40% for t-tau, 37.5% for p-tau181 and 56% for p-tau199. Improvement of the diagnostic accuracy upon logistic regression analysis with t-tau and p-tau199 as independent variables showed that 22 out of 25 FTLD patients could be correctly classified. In conclusion, none of the markers per se fulfilled the criteria for the „ideal“ marker (sensitivity and specificity higher than 85%). However, combination of t-tau and p-tau199 classified correctly 88% of FTLD patients, thus largely satisfying practical requirements.

Keywords: Alzheimer’s disease; Frontotemporal lobar degeneration; Cerebrospinal fluid; ELISA; Phosphorylation; Tau proteins

  • [1] Galton C.J., Patterson K., Xuereb J.H., Hodges J.R., Atypical and typical presentations of Alzheimer’s disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases, Brain, 2000, 3, 484–498 http://dx.doi.org/10.1093/brain/123.3.484CrossrefGoogle Scholar

  • [2] McKhann G.M., Albert M.S., Grossman M., Miller B., Dickson D., Trojanowski J.Q., Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick’s Disease, Arch. Neurol., 2001, 58, 1803–1809 http://dx.doi.org/10.1001/archneur.58.11.1803CrossrefGoogle Scholar

  • [3] Zhukareva V., Vogelsberg-Ragaglia V., Van Deerlin V.M., Bruce J., Shuck T., Grossman M., et al., Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia, Ann. Neurol., 2001, 49, 165–175 http://dx.doi.org/10.1002/1531-8249(20010201)49:2<165::AID-ANA36>3.0.CO;2-3CrossrefGoogle Scholar

  • [4] Zhukareva V., Sundarraj S., Mann D., Sjögren M., Blenow K., Clark C.M., et al., Selective reduction of soluble tau proteins in sporadic and familial frontotemporal dementias: an international follow-up study. Acta Neuropathol., 2003, 105, 469–476 Google Scholar

  • [5] Itoh N., Arai H., Urakami K., Ishiguro K., Ohno H., Hampel H., et al., Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer’s disease, Ann. Neurol., 2001, 50, 150–156 http://dx.doi.org/10.1002/ana.1054CrossrefGoogle Scholar

  • [6] Pijnenburg Y.A., Schoonenboom N.S., Rosso S.M., Mulder C., Van Kamp G.J., Van Swieten J.C., et al., CSF tau and Abeta42 are not useful in the diagnosis of frontotemporal lobar degeneration, Neurology, 2004, 62, 1649 CrossrefGoogle Scholar

  • [7] Schoonenboom N.S., Pijnenburg Y.A., Mulder C., Rosso S.M., Van Elk E.J., Van Kamp G.J., et al., Amyloid β (1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease, Neurology, 2004, 62, 1580–1584 Google Scholar

  • [8] De Jong D., Jansen R.W., Pijnenburg Y.A., van Geel W.J., Borm G.F., Kremer H.P., et al., CSF neurofilament proteins in the differential diagnosis of dementia, J. Neurol. Neurosurg. Psychiatry, 2007, 78, 936–938 http://dx.doi.org/10.1136/jnnp.2006.107326CrossrefGoogle Scholar

  • [9] McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M., Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease, Neurology, 1984, 34, 939–944 CrossrefGoogle Scholar

  • [10] Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S., et al., Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria, Neurology 1998, 51, 1546–1554 CrossrefGoogle Scholar

  • [11] Schonknecht P., Pantel J., Werle E., Hartmann T., Essig M., Baudendistel K., et al., Cerebrospinal fluid protein tau levels in the differential diagnosis of Alzheimer’s disease, Fortschr. Neurol. Psychiatr., 2000, 68, 439–446 (in German) http://dx.doi.org/10.1055/s-2000-7732CrossrefGoogle Scholar

  • [12] The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging Working Group, Consensus report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”, Neurobiol. Aging, 1998, 19, 109–116 http://dx.doi.org/10.1016/S0197-4580(98)00022-0CrossrefGoogle Scholar

  • [13] Pijnenburg Y.A., Janssen J.C., Schoonenboom N.S., Petzold A., Mulder C., Stigbrand T., et al., CSF neurofilaments in frontotemporal dementia compared with early onset Alzheimer’s disease and controls. Dement. Geriatr. Cogn. Disord., 2007, 23, 225–230 http://dx.doi.org/10.1159/000099473CrossrefGoogle Scholar

  • [14] Forman M.S., Zhukareva V., Bergeron C., Chin S.S., Grossman M., Clark C., et al., Signature tau neuropathology in gray and white matter of corticobasal degeneration, Am. J. Pathol., 2002, 160, 2045–2053 CrossrefGoogle Scholar

  • [15] Tumani H., Nau R., Felgenhauer K., Beta-trace protein in cerebrospinal fluid: a blood-CSF barrier-related evaluation in neurological diseases, Ann. Neurol. 1998, 44, 882–889 http://dx.doi.org/10.1002/ana.410440606CrossrefGoogle Scholar

  • [16] Reiber H., CSF flow — its influence on CSF concentration of brain-derived and blood-derived proteins. In: Teelken A., Korf J. (Eds.), Neurochemistry, Plenum Press, New York, 1997, 423–432 Google Scholar

  • [17] Tapiola T., Overmyer M., Lehtovirta M., Helisalmi S., Ramberg J., Alafuzoff I., et al., The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer’s disease, Neuroreport, 1997, 8, 3961–3963 http://dx.doi.org/10.1097/00001756-199712220-00022CrossrefGoogle Scholar

  • [18] Riemenschneider M., Wagenpfeil S., Diehl J., Lautenschlager N., Theml T., Heldmann B., et al., Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration, Neurology, 2002, 58, 1622–1628 CrossrefGoogle Scholar

  • [19] Fabre S.F., Forsell C., Viitanen M., Sjögren M, Wallin A, Blennow K., et al., Clinic-based cases with frontotemporal dementia show increased cerebrospinal fluid tau and high apolipoprotein E epsilon4 frequency, but no tau gene mutations, Exp. Neurol., 2001, 168, 413–418 http://dx.doi.org/10.1006/exnr.2000.7613Google Scholar

  • [20] Rosso S.M., van Herpen E., Heutink P., Total tau is not increased in cerebrospinal fluid of frontotemporal dementia patients with P301L and G272V tau mutations, Neurobiol. Aging, 2002, 23, S379 Google Scholar

  • [21] Rosso S.M., van Herpen E., Pijnenburg Y.A., Schoonenboom N.S., Scheltens P., Heutink P., et al., Total tau and phosphorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutations, Arch. Neurol. 2003, 60, 1209–1213 http://dx.doi.org/10.1001/archneur.60.9.1209CrossrefGoogle Scholar

  • [22] Buée L., Bussière T., Buée-Scherrer V., Delacourte A., Hof P.R., Tau protein isoforms, phosphorylation and role in neurodegenerative disorders, Brain Res. Rev., 2000, 33, 95–130 http://dx.doi.org/10.1016/S0165-0173(00)00019-9CrossrefGoogle Scholar

  • [23] Kertesz A., McMonagle P., Blair M., Davidson W., Munoz D.G., The evolution and pathology of frontotemporal dementia, Brain, 2005, 128, 1996–2005 http://dx.doi.org/10.1093/brain/awh598CrossrefGoogle Scholar

  • [24] Varma A.R., Snowden J.S., Lloyd J.J., Talbot P.R., Mann D.M., Neary D., Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer’s disease and frontotemporal dementia, J. Neurol. Neurosurg. Psychiatry, 1999, 66, 184–188 http://dx.doi.org/10.1136/jnnp.66.2.184CrossrefGoogle Scholar

  • [25] Bürger K., Zinkowski R., Teipel S.J., Tapiola T., Arai H., Blennow K., et al., Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231, Arch. Neurol., 2002, 59, 1267–1272 http://dx.doi.org/10.1001/archneur.59.8.1267CrossrefGoogle Scholar

  • [26] Hampel H., Teipel S.J., Total and phosphorylated tau proteins: evaluation as core bomarker candidates in frontotemporal dementia, Dement. Geriatr. Cogn. Disord., 2004, 17, 350–354 http://dx.doi.org/10.1159/000077170CrossrefGoogle Scholar

  • [27] Blennow K., Vanmechelen E., Hampel H., CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer’s disease. Mol. Neurobiol., 2001, 24, 87–97 http://dx.doi.org/10.1385/MN:24:1-3:087CrossrefGoogle Scholar

  • [28] Grossman M., Farmer J., Leight S., Work M., Moore P., Van Deerlin V., et al., Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer’s disease, Ann. Neurol., 2005, 57, 721–729 http://dx.doi.org/10.1002/ana.20477CrossrefGoogle Scholar

  • [29] Bürger K., Zinkowski R., Teipel S.J., Arai H., DeBernardis J., Kerkman D., et al., Differentiation of geriatric major depression from Alzheimer’s disease with CSF tau protein phosphorylated at threonine 231, Am. J. Psychiatry, 2003, 160, 376–379 http://dx.doi.org/10.1176/appi.ajp.160.2.376CrossrefGoogle Scholar

  • [30] Bian H., Van Swieten J.C., Leight S., Massimo L., Wood E., Forman M., et al., CSF biomarkers in frontotemporal lobar degeneration with known pathology, Neurology, 2008, 70, 1827–1835 http://dx.doi.org/10.1212/01.wnl.0000311445.21321.fcCrossrefGoogle Scholar

  • [31] Augustinack J.C., Schneider A., Mandelkow E.M., Hyman B.T., Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer’s disease, Acta Neuropathol., 2002;103:26–35. http://dx.doi.org/10.1007/s004010100423CrossrefGoogle Scholar

  • [32] Boban M., Grbić K., Mladinov M., Hof P.R., Süssmair C. Ackl N., et al., Cerebrospinal fluid markers in differential diagnosis of Alzheimer’s disease and vascular dementia, Coll. Antropol., 2008, 32, 31–36 Google Scholar

  • [33] Hampel H., Bürger K., Zinkowski R., Teipel S.J., Görnitz A., Andreasen N., et al., Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study, Arch. Gen. Psychiatry, 2004, 61, 95–102 http://dx.doi.org/10.1001/archpsyc.61.1.95CrossrefGoogle Scholar

  • [34] Matsuo E.S., Shin R.W., Billingsley M.L., Van deVoorde A., O’Connor M., Trojanowski J.Q., et al., Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer’s disease paired helical filament tau, Neuron, 1994, 13, 989–1002 http://dx.doi.org/10.1016/0896-6273(94)90264-XCrossrefGoogle Scholar

About the article

Published Online: 2010-10-12

Published in Print: 2010-03-01

Citation Information: Translational Neuroscience, Volume 1, Issue 1, Pages 43–48, ISSN (Online) 2081-6936, ISSN (Print) 2081-3856, DOI: https://doi.org/10.2478/v10134-010-0013-z.

Export Citation

© 2010 Versita Warsaw. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. BY-NC-ND 3.0

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

Goran Šimić, Mirjana Babić Leko, Selina Wray, Charles R. Harrington, Ivana Delalle, Nataša Jovanov-Milošević, Danira Bažadona, Luc Buée, Rohan de Silva, Giuseppe Di Giovanni, Claude M. Wischik, and Patrick R. Hof
Progress in Neurobiology, 2017, Volume 151, Page 101
Mirjana Babić Leko, Fran Borovečki, Nenad Dejanović, Patrick R. Hof, Goran Šimić, and Angel Cedazo-Minguez
Journal of Alzheimer's Disease, 2016, Volume 50, Number 3, Page 765
Elizabeta B Mukaetova-Ladinska, Mosi Li, and Raj N Kalaria
Future Neurology, 2015, Volume 10, Number 6, Page 559
Mirjana Babić, Željka Vogrinc, Andrea Diana, Nataša Klepac, Fran Borovečki, Patrick Hof, and Goran Šimić
Translational Neuroscience, 2013, Volume 4, Number 2

Comments (0)

Please log in or register to comment.
Log in